Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Battelle Pulmonary Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Battelle believes its electrohydrodynamic (EHD) technology can deliver drugs to the lung to treat asthma, emphysema, cancers of the lung, and other conditions more effectively than existing commercial inhalation systems. Drug companies are interested, as evidenced by the company's deals with Pfizer, the Ross Products division of Abbott, and others. Battelle is partnering EHD and also developing an internally developed inhaled chemotherapy system on its own.

You may also be interested in...



Science Matters: Harnessing The Inherent Power Of MAIT Cells

Tapping into the interplay between gut microbiota and an underappreciated subset of T cells could lead to therapies in a range of diseases.

Oncology Market Trends: Predictive Biomarkers, New IO Targets And Tougher Competition

Higher success rates in rare cancers, where biomarkers can better direct therapy, characterize the oncology treatment landscape. Deal-making is favoring alliances over acquisitions as drugmakers focus on establishing the clinical benefit of new targets, particularly for rare indications.

Two Very Different Flavors Of Ocular Gene Therapy Get A Boost

The 2021 collaboration between Abbvie and Regenxbio to develop an anti-VEGF gene therapy for chronic retinal diseases is a noteworthy deal in the gene therapy space. But for both clinical and commercial reasons, it is a one-off opportunity and not an indicator of the overall potential of gene therapies to address eye diseases. Interest in optogenetics, however, which is the introduction of light-sensing genes into cells in the eye to restore vison, may be on the rise.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC090371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel